The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
1
|
N | Nervous system | |
2
|
N04 | Anti-parkinson drugs | |
3
|
N04B | Dopaminergic agents | |
4
|
N04BC | Dopamine agonists | |
5
|
N04BC09 | Rotigotine |
The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.
| Code | Route | Amount | Notes |
|---|---|---|---|
| T-DERMAL | Transdermal | 6 mg |
| Active Ingredient |
|---|
|
Rotigotine is a non-ergolinic dopamine agonist for the treatment of signs and symptoms of Parkinson’s disease and Restless Legs Syndrome. |
| Document | Type | Information Source | |
|---|---|---|---|
| NEUPRO 1mg/24h, 3mg/24h Transdermal patch | MPI, EU: SmPC | European Medicines Agency (EU) | |
| NEUPRO 2mg/24h Transdermal patch | MPI, EU: SmPC | European Medicines Agency (EU) | |
| NEUPRO 4mg/24h, 6mg/24h, 8mg/24h Transdermal patch | MPI, EU: SmPC | European Medicines Agency (EU) |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.